Apogee Therapeutics Inc. (NASDAQ:APGE) Given Consensus Rating of “Moderate Buy” by Brokerages

Apogee Therapeutics Inc. (NASDAQ:APGE) has earned an average recommendation of “Moderate Buy” from the seventeen analysts that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, nine have assigned a buy rating and three have assigned a strong buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $110.4286.

APGE has been the subject of several analyst reports. Guggenheim raised their target price on Apogee Therapeutics from $130.00 to $160.00 and gave the stock a “buy” rating in a research report on Tuesday. Stephens began coverage on Apogee Therapeutics in a research report on Tuesday, December 16th. They issued an “overweight” rating and a $95.00 price target on the stock. Wolfe Research assumed coverage on Apogee Therapeutics in a research note on Wednesday, January 7th. They set a “peer perform” rating for the company. Stifel Nicolaus set a $133.00 price objective on Apogee Therapeutics in a report on Tuesday, January 6th. Finally, Wall Street Zen downgraded shares of Apogee Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, December 6th.

Trending Headlines about Apogee Therapeutics

Here are the key news stories impacting Apogee Therapeutics this week:

• Positive Sentiment: Positive 52‑week Phase 2 Part A data for zumilokibart (APG777) showed durable maintenance and deepening of responses with every‑3‑month and every‑6‑month dosing (e.g., 75% and 85% maintained EASI‑75), supporting the drug’s infrequent‑dosing value proposition. GlobeNewswire: 52‑Week Data
• Positive Sentiment: Analysts reacted quickly with multiple buy ratings and big price‑target increases (Guggenheim, Canaccord, Citi, BTIG), lifting sentiment that the program could support late‑stage development or M&A interest. Benzinga: Analyst Upgrades
• Positive Sentiment: Investor write‑ups and media coverage highlighted the favorable maintenance results and potential next catalysts (Part B induction data in Q2 and possible phase‑3 start in H2 2026), sustaining bullish narrative. Seeking Alpha: Strong Buy / Catalyst Summary
• Neutral Sentiment: Company held a conference call/webcast to review the Part A 52‑week data, providing more transparency on durability and safety that investors can digest for modeling. GlobeNewswire: Conference Call
• Neutral Sentiment: Short‑interest notices in the feed show zero reported short shares (likely a data artifact); they do not provide meaningful evidence of positioning pressure.
• Negative Sentiment: Apogee announced a proposed $300 million underwritten public offering (with up to $45M option), which raises dilution risk and often triggers selling pressure after a rally — the most likely proximate cause of the intraday pullback. GlobeNewswire: Offering Announcement

Insider Activity at Apogee Therapeutics

In other Apogee Therapeutics news, Director Fairmount Funds Management Llc sold 1,750,000 shares of the business’s stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $76.30, for a total value of $133,525,000.00. Following the transaction, the director directly owned 298,647 shares in the company, valued at $22,786,766.10. The trade was a 85.42% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Carl Dambkowski sold 18,700 shares of the company’s stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $77.84, for a total transaction of $1,455,608.00. Following the sale, the insider directly owned 212,523 shares in the company, valued at $16,542,790.32. This represents a 8.09% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 1,839,700 shares of company stock valued at $140,118,083 in the last ninety days. Insiders own 42.77% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Rockefeller Capital Management L.P. bought a new stake in Apogee Therapeutics during the 4th quarter worth approximately $25,000. ANTIPODES PARTNERS Ltd raised its position in Apogee Therapeutics by 41.2% in the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 843 shares of the company’s stock valued at $33,000 after purchasing an additional 246 shares during the last quarter. Los Angeles Capital Management LLC bought a new position in Apogee Therapeutics in the 4th quarter valued at $37,000. Quantbot Technologies LP acquired a new position in Apogee Therapeutics in the third quarter worth $96,000. Finally, Seven Fleet Capital Management LP bought a new stake in shares of Apogee Therapeutics during the fourth quarter worth $136,000. 79.04% of the stock is owned by institutional investors and hedge funds.

Apogee Therapeutics Stock Down 7.9%

NASDAQ APGE opened at $73.00 on Wednesday. Apogee Therapeutics has a twelve month low of $26.20 and a twelve month high of $84.56. The stock has a market cap of $5.07 billion, a P/E ratio of -17.30 and a beta of 1.39. The company’s 50-day simple moving average is $71.16 and its 200 day simple moving average is $63.95.

Apogee Therapeutics (NASDAQ:APGE) last announced its quarterly earnings results on Monday, March 2nd. The company reported ($1.03) EPS for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.02. Research analysts anticipate that Apogee Therapeutics will post -3.09 earnings per share for the current year.

About Apogee Therapeutics

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.